Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Latest Information Update: 13 Feb 2024
At a glance
- Drugs TmPSMA 02 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
Most Recent Events
- 02 Feb 2024 Planned End Date changed from 2 Jan 2042 to 31 Jan 2042.
- 02 Feb 2024 Planned primary completion date changed from 2 Jan 2027 to 31 Jan 2027.
- 02 Feb 2024 Status changed from not yet recruiting to recruiting.